Cited by 50Cancer Cells and MetastasisCancer-related Molecular PathwaysCellular Mechanics and Interactions

CDKN2A inhibits formation of homotypic cell-in-cell structures

Open access
Liang, Jianqing, Fan, Jie, Wang, Manna, Niu, Zubiao, Zhang, Zhengrong, Yuan, Long, Tai, Yanhong, Chen, Zhaolie +5 more·2018·Oncogenesis

Abstract

Cell-in-cell (CIC) structures, characterized by enclosure of one or more cells within another cell, were extensively documented in human cancers. Although elevated CIC formation was found in cancers with CDKN2A inactivation, a causal link between them remains to be established. We reported here that inhibiting CDKN2A expression effectively promoted homotypic CIC formation, whereas ectopic overexpression of p16INK4a or p14ARF, two proteins encoded by CDKN2A gene, significantly suppressed CIC formation in MCF7 cells. The regulation of CIC formation by CDKN2A was tightly correlated with subcellular redistribution of E-cadherin, F-actin rearrangement and reduced phosphorylation of myosin light chain 2 (p-MLC2), consistent with which, CDKN2A expression imparted cells winner/outer identity in competition assay. Moreover, CIC formation negatively correlates with p16INK4a expression in human breast cancers. Thus, our work identifies CDKN2A as the first tumor suppressor whose inactivation promotes homotypic CIC formation in human cancer cells.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41389-018-0056-4

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CDKN2A promotes apoptosis and senescence, inhibits cell-in-cell structure formation and anchorage-independent growth, and modulates anti-tumor immunity by influencing immune-cell infiltration.

    “Additionally, CDKN2A promotes apoptosis and senescence and inhibits cancer-associated processes like cell-in-cell structure formation and anchorage-independent growth, while it modulates anti-tumor immunity by influencing immune-cell infiltration [38,58,109,111].”

    From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [38]

    The Results (no page number available) show that CDKN2A expression inhibits cell-in-cell formation and note that persistent expression is known to induce senescence. The Discussion links inhibition of cell-in-cell formation to increased anchorage-independent growth, but does not directly show that CDKN2A inhibits that growth. The paper does not support the attributed claims about CDKN2A promoting apoptosis or modulating anti-tumor immunity through immune-cell infiltration. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Liang, J., Fan, J., Wang, M., Niu, Z., Zhang, Z., Yuan, L., Tai, Y., Chen, Z., Song, S., Wang, X., Liu, X., Huang, H., & Sun, Q.
Affiliations
  • Capital Medical University (CN)
  • 307th Hospital of Chinese People’s Liberation Army (CN)
  • South China University of Technology (CN)
Corresponding author
  • Liu, Xiaoqing
  • Huang, Hongyan
  • Sun, Qiang
Venue
Oncogenesis
Published
2018-06-05
Volume
7
Issue
6
Pages
50-50
ISSN
2157-9024 (ISSN-L)
OpenAlex
W2808191735
Cited by
49
References
27
Citations by year
2026: 2 · 2025: 7 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 4 · 2020: 4 · 2019: 4 · 2018: 2
FWCI
1.32
Type
journal article
Language
en
Open access
Locations
  • Oncogenesis (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Memorial Sloan-Kettering Cancer Center
  • National Natural Science Foundation of China (81372834, 31671432, 31770975, 81471578, 81472588, 81572799)
  • National Key Research and Development Program of China (2015CB553704)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
Keywords
CDKN2A, cell-in-cell structures, p16INK4a, p14ARF, tumor suppressor inactivation, F-actin rearrangement, myosin light chain 2 phosphorylation, MCF-7 cells, breast cancer, cell competition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review